Enanta Pharmaceuticals (ENTA) Price & Analysis

Compare

190 Followers

ENTA Stock Chart & Stats

$14.51

-$0.16(-2.97%)

At close: Jan 08 4:00 PM EST

$14.51

-$0.16(-2.97%)

Day’s Range― - ―

52-Week Range$4.09 - $17.15

Previous CloseN/A

Volume330.58K

Average Volume (3M)189.18K

Market Cap

$421.07M

Enterprise Value$492.62M

Total Cash (Recent Filing)$185.85M

Total Debt (Recent Filing)$193.18M

Price to Earnings (P/E)―

Beta1.62

Next Earnings

May 11, 2026

EPS Estimate

-0.51

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.42

Shares Outstanding29,019,344

10 Day Avg. Volume182,944

30 Day Avg. Volume189,176

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)3.95

Price to Sales (P/S)3.91

P/FCF Ratio-7.94

Enterprise Value/Market Cap1.17

Enterprise Value/Revenue7.35

Enterprise Value/Gross Profit7.35

Enterprise Value/Ebitda-8.35

Forecast

1Y Price Target

$19.50

Price Target Upside34.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-2.65

Revenue Forecast (FY)$64.89M

Bulls Say, Bears Say

Bulls Say

Pipeline Diversification And Combination PotentialAn expanding immunology pipeline, including a KIT inhibitor nearing first-in-human data, a newly nominated MRGPRX2 program, and a second oral antiviral plus EDP-323 for post-exposure prevention, broadens commercial opportunities and supports potential combination approaches.

Positive Clinical ResultsPhase 2b results for zelicapavir demonstrated clinically meaningful efficacy with consistent virologic and safety findings, supporting the case that the drug could be approvable if replicated in a pivotal trial.

Regulatory Strategy ClarityActive regulatory engagement that could permit a single pivotal trial would provide clarity for zelicapavir's late-stage development and streamline the path toward approval.

Bears Say

Development And Execution RiskApproval hinges on replication of positive Phase 2b findings in a pivotal trial, and clinical development uncertainty, commercial execution challenges and intellectual property risks could prevent achievement of analyst price targets.

Funding And Partnership UncertaintyUncertainty about whether a development partner is required to initiate a pivotal trial raises the risk that progression to a Phase 3 study could be delayed or constrained by limited internal funding.

Regulatory Headline-driven VolatilityHeadlines from a senior regulatory official about infant RSV vaccines generated share volatility and negative sentiment that can pressure the stock irrespective of the company's antiviral focus.

Enanta Pharmaceuticals News

Enanta files $150M mixed securities shelf

16:45 EST Enanta (ENTA) files $150M mixed securities shelf Published first on TheFly – the ultimate source for...

20d ago

ENTA

Enanta reports Q1 EPS (42c), consensus (88c)

Reports Q1 revenue $18.6M, consensus $15.3M. Enanta’s (ENTA) cash, cash equivalents and short-term and long-term marketable securities totaled...

22d ago

ENTA

Enanta Pharmaceuticals: RSV Monoclonal Headwinds Turn Tailwind for Zelicapavir Treatment Opportunity

Enanta Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from...

12d ago

ENTA

Enanta Pharmaceuticals (ENTA) Q1 Earnings Cheat Sheet

Enanta Pharmaceuticals (ENTA) is scheduled to report 1st quarter earnings on 02/09/2026. Regarding Q1 estimates, Wall Street analysts...

25d ago

ENTA

Enanta Pharmaceuticals: Promising Pipeline and Strong Financial Position Justify Buy Rating

H.C. Wainwright analyst Brandon Folkes has reiterated their bullish stance on ENTA stock, giving a Buy rating on...

4M ago

ENTA

Enanta Pharmaceuticals Reports Progress in Drug Development

Enanta Pharmaceuticals ( ($ENTA) ) has released its Q4 earnings. Here is a breakdown of the information Enanta...

4M ago

ENTA

Enanta reports Q4 EPS (87c), consensus ($1.01)

Reports Q4 revenue $15.1M, consensus $15.97M. “This past quarter marked a pivotal period for Enanta (ENTA), with significant...

4M ago

ENTA

Is ENTA a Buy, Before Earnings?

Enanta Pharmaceuticals (ENTA) is scheduled to report 4th quarter earnings on 11/17/2025. Regarding Q4 estimates, Wall Street analysts...

4M ago

ENTA

Buy Rating for Enanta Pharmaceuticals Driven by Promising RSV Drug Pipeline and Market Potential

Enanta Pharmaceuticals (ENTA) has received a new Buy rating, initiated by J.P. Morgan analyst, Anupam Rama. Anupam Rama...

4M ago

ENTA

Enanta initiated with an Overweight at JPMorgan

JPMorgan initiated coverage of Enanta (ENTA) with an Overweight rating and $17 price target The firm cites the...

4M ago

ENTA

Enanta Pharmaceuticals Announces Public Stock Offering

Enanta Pharmaceuticals ( ($ENTA) ) has issued an update. On September 30, 2025, Enanta Pharmaceuticals announced a public...

5M ago

ENTA

Enanta upgraded to Buy from Hold at Jefferies

Jefferies analyst Akash Tewari upgraded Enanta (ENTA) to Buy from Hold with a price target of $20, up...

5M ago

ENTA

Enanta upgraded to Buy at Jefferies on higher confidence in RSV antiviral

As previously reported, Jefferies upgraded Enanta (ENTA) to Buy from Hold with a price target of $20, up...

5M ago

ENTA

Enanta 6.5M share Spot Secondary priced at $10.00

The deal size was increased to $65M from $50M and priced at low end of $10.00-$10.50 target range....

5M ago

ENTA

ENTA FAQ

What was Enanta Pharmaceuticals’s price range in the past 12 months?

Enanta Pharmaceuticals lowest stock price was $4.09 and its highest was $17.15 in the past 12 months.

What is Enanta Pharmaceuticals’s market cap?

Enanta Pharmaceuticals’s market cap is $421.07M.

When is Enanta Pharmaceuticals’s upcoming earnings report date?

Enanta Pharmaceuticals’s upcoming earnings report date is May 11, 2026 which is in 68 days.

How were Enanta Pharmaceuticals’s earnings last quarter?

Enanta Pharmaceuticals released its earnings results on Feb 09, 2026. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.768 by $0.348.

Is Enanta Pharmaceuticals overvalued?

According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Enanta Pharmaceuticals pay dividends?

Enanta Pharmaceuticals does not currently pay dividends.

What is Enanta Pharmaceuticals’s EPS estimate?

Enanta Pharmaceuticals’s EPS estimate is -0.51.

How many shares outstanding does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals has 29,019,344 shares outstanding.

What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?

Enanta Pharmaceuticals reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.768. Following the earnings report the stock price went up 2.169%.

Which hedge fund is a major shareholder of Enanta Pharmaceuticals?

Currently, no hedge funds are holding shares in ENTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Enanta Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-60.01%

Trailing 12-Months

Asset Growth

-5.49%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals (ENTA) Earnings & Revenues

Historic Earnings Reports

ENTA Stock 12 Month Forecast

Average Price Target

$19.50

▲(34.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.19,13.713846153846154,14.237692307692306,14.76153846153846,15.285384615384615,15.80923076923077,16.333076923076923,16.856923076923078,17.380769230769232,17.904615384615383,18.428461538461537,18.95230769230769,19.476153846153846,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.19,13.675384615384615,14.16076923076923,14.646153846153846,15.131538461538462,15.616923076923076,16.10230769230769,16.587692307692308,17.073076923076922,17.558461538461536,18.043846153846154,18.529230769230768,19.014615384615382,{"y":19.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.19,13.636923076923077,14.083846153846153,14.53076923076923,14.977692307692308,15.424615384615384,15.871538461538462,16.318461538461538,16.765384615384615,17.212307692307693,17.659230769230767,18.106153846153845,18.553076923076922,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.11,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.14,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.19,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >